There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.
公开了一种新的5,7-二取代[1,3]
噻唑并[4,5-d]
嘧啶-2(3H)-酮衍
生物的
化学式(I),其中R1、R2、R3、R4和R5在规范中定义,并且其药学上可接受的盐,以及其制备过程、包含它们的制药组合物和它们在治疗中的用途。化合物(I)是CX3CR1受体拮抗剂,因此在治疗或预防神经退行性疾病、脱髓鞘性疾病、心血管和脑血管动脉粥样硬化性疾病、外周动脉疾病、类风湿性关节炎、慢性阻塞性肺疾病、哮喘或疼痛方面特别有用。